03/06/2026
Big MS research news just dropped on a drug we’ve been watching for YEARS — and I want to help you understand what it actually means for you 🧡
A new BTK-inhibitor medication being studied for multiple sclerosis — called Fenebrutinib — just showed promising results in a large research study in people w/ relapsing MS.
In the trial, people taking Fenebrutinib had 51% fewer relapses compared to people taking another MS medication called teriflunomide/Aubagio.
Researchers are excited about this drug because it works in a slightly different way than many current MS treatments… It’s designed to reach the brain & spinal cord and target immune cells involved in MS activity.
Even more interesting: the medication is being studied for both relapsing MS & primary progressive MS, which is something researchers are always working hard to improve treatment options for!
That said — there’s still more to learn.
Researchers are continuing to review safety data, and the full study results will be presented at the American Academy of Neurology (AAN) conference in 2026 before any decisions are made about approval.
Research updates like this are super exciting.
But what matters most is understanding what they actually mean — and what they don’t.
If you’d like a simple breakdown of:
🔸 what this type of medication does
🔸 what “relapse reduction” really means
🔸 how this compares to current MS treatments
Comment “BTK” and I’ll send it to you. 🤍
This is for educational purposes only. Your MS journey is unique - always loop in your care team before making any treatment decisions.
MSAwareness